Please login to the form below

Not currently logged in
Email:
Password:

acute myeloid leukaemia

This page shows the latest acute myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

The drug has been approved for chronic lymphocytic leukaemia (CLL) since 2016 and picked up a second indication in acute myeloid leukaemia (AML) last year, but analyst Steve Scala at Cowen

Latest news

More from news
Approximately 2 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    8. Daurismo – a new wave of AML treatment. After many years with no new therapies, the treatment of acute myeloid leukaemia (AML) is set for rapid change, thanks to a wave ... as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL),

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... 1, 000. CoLucid. Lilly. Company acquisition.

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Commercial milestones of up to $150m. Lead product has completed phase II in acute myeloid leukaemia.

  • Deal Watch August 2016 Deal Watch August 2016

    540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute myeloid leukaemia. ... 151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor)

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics